logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

CureVac Has Very Interesting Future Plans

CureVac CureVac B.V. ( CVAC ) is a global biopharmaceutical company specializing in messenger RNA ( mRNA ) technology. The firm has more than 20 years of expertise in developing and optimizing versatile biological molecules for prevention and treatment purposes....

Read More

March 22, 2021

0

Negative News from Ionis Pharmaceuticals Phase 3 Trial for Huntington's Disease. Good News from the Regeneron Antibody Cocktail for COVID-19

Negative News from Ionis Pharmaceuticals  Ionis Pharmaceuticals ( IONS ) announced that its partner, Roche ( RHHBY ) , has decided to discontinue dosing in the Phase 3 GENERATION HD1 study of tominersen for Huntington's disease (HD). A pre-planned review...

Read More

March 23, 2021

0

CureVac Lawsuit Against BioNTech and Subsidiaries, Seeking Fair Compensation for Infringement of Intellectual Property

CureVac N.V. Files Lawsuit Against BioNTech for Infringement  CureVac N.V. ( CVAC ), a company that develops therapeutics based on messenger ribonucleic acid ( mRNA ), has moved to assert its intellectual property rights that have been accumulated over more...

Read More

July 5, 2022

0

BrainStorm Cell Therapeutics: Another Clinical-Stage Small Firm's Product for the Devastating Disease ALS

BrainStorm Cell Therapeutics Inc BrainStorm Cell Therapeutics Inc ( BCLI ) develops innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn® technology platform used to produce autologous...

Read More

March 27, 2023

0

The U.S. FDA Accepted Checkpoint Therapeutics Biotech BLA for Cosibelimab

Checkpoint Therapeutics Checkpoint Therapeutics ( CKPT ) is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. Checkpoint is evaluating its lead antibody product candidate, cosibelimab,...

Read More

March 31, 2023

0

Vertex Pharmaceuticals to Acquire ViaCyte Inc to Accelerate its Potentially Curative VX-880 Programs in Type 1 Diabetes

Vertex Pharmaceuticals and ViaCyte Inc are in the NEWS Vertex Pharmaceuticals ( VRTX ) entered into a definitive agreement under which it will acquire ViaCyte, a private biotechnology company focused on delivering novel stem cell-derived cell replacement therapies as a functional...

Read More

July 12, 2022

0

The EU CHMP Agency Recommended Approval of TG Therapeutics Firm's BRIUMVI™ for Relapsing Forms of MS in Adults

TG Therapeutics TG Therapeutics, Inc. ( TGTX ) announced today that the Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has issued a positive opinion recommending the approval of BRIUMVITM...

Read More

March 31, 2023

0

Illumina Acquisition of GRAIL: A Challenging Story That Boosted ILMN's Stock Price

Illumina Acquisition of GRAIL On September 21, 2020 , Illumina and GRAIL Inc. announced that they entered into a definitive agreement under which Illumina will acquire GRAIL for cash and stock consideration of $8 billion, upon closing of the transaction. On...

Read More

March 31, 2021

0

Clene Inc: More Promising News for ALS Patients

The clinical-stage Clene Nanomedicine Firm Reported Significantly Decreased Mortality in Amyotrophic Lateral Sclerosis (ALS) CNM-Au8® treatment resulted in a significant survival benefit (5 CNM-Au8 deaths vs 14 placebo deaths CNM-Au8 treatment was well-tolerated, with no significant safety findings  during this trial...

Read More

July 14, 2022

0

Vertex and CRISPR Complete Submission of BLAs to the US FDA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals and CRISPR Therapeutics Completion of BLAs Vertex Pharmaceuticals ( VRTX ) and CRISPR Therapeutics ( CRSP ) announced the completion of the rolling Biologics License Applications ( BLAs ) to the FDA for the investigational treatment exagamglogene autotemcel...

Read More

April 3, 2023

0

  • Previous
  • 1
  • 2
  • ...
  • 134
  • 135
  • 136
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy